Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Scope Firms, FDA Faulted In 300-Page Senate Report Seeking Device Reforms

This article was originally published in The Gray Sheet

Executive Summary

Senate HELP Ranking Member Sen. Patty Murray in a staff report criticizes FDA and manufacturers for reacting slowly to duodenoscope contamination incidents in 2013. The report says FDA needs a more robust device surveillance system and calls for more attention to 510(k) modification policies. Murray is a key partner in ongoing Senate work to produce a so-called "medical innovation" bill.

You may also be interested in...



Olympus, Pentax Working On Responses To Sen. Murray Duodenoscope Contamination Concerns

Two duodenoscope manufacturers – Olympus and Pentax – this week joined Fujifilm in saying they are aware of Senate HELP Committee ranking member Patty Murray’s concerns about recently released duodenoscope contamination levels and are working to complete postmarket surveillance studies of their devices, as required by the US FDA.

US Senators Press Agency Witnesses On Adding UDIs To Claims Forms

Democratic Sens. Patty Murray and Elizabeth Warren pressed US CMS and HHS officials at a recent hearing on making certain a line is added to Medicare claims forms for unique device identifiers, both to reduce Medicare costs and improve patient safety.

Industry Urges Caution In Response To Growing Push For 'Real-World' Device Evaluation System

AdvaMed's new chief Scott Whitaker says industry doesn't want to sign onto a new "national evaluation system" for devices championed by FDA until it is convinced that the initiative will enhance, rather than hinder, premarket product development.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT034884

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel